Egfr-Mutated Disease

MADRID — A novel antibody-drug conjugate plus osimertinib showed clinical activity and a manageable safety profile in patients with relapsed/refractory, EGFR-mutated non-small cell lung cancer, according to a presentation at ESMO Congress.

In this video, Thomas Waddington, MD, assistant clinical professor in the department of medicine, division of pulmonary and critical care medicine at City of Hope National Medical Center, speaks with Healio about what pulmonologists should know about EGFR mutations in lung cancer.

In an interview with Nephrology News & Issues, Cynthia Delgado, MD, FASN, said the first report on the inclusion of race in eGFR was published 22 years ago following the results of the Modification of Diet in Renal Disease Study.

It has been a busy time in the debate over equity in kidney care.

The addition of plinabulin to docetaxel during second- or third-line treatment significantly extended OS for patients with EGFR wild-type non-small cell lung cancer, according to topline data released by the agent’s manufacturer.

With multiple approvals and more treatments in the pipeline, there have been “amazing” advances in lung cancer treatment over the past year, Roy Herbst, MD, PhD, told Healio.